In order to expand its rare disease pipeline, Biogen has entered into a collaboration with Stoke Therapeutics for the development and commercialisation of zorevunersen for the treatment of Dravet Syndrome. The deal, which is worth up to US$550 M, will provide Biogen with rights to commercialise the antisense oligonucleotide globally, excluding in the US, Canada, and Mexico where Stoke will retain rights. The companies will leverage Stoke’s Targeted Augmentation of Nuclear Gene Output (TANGO) platform which aims to address protein deficiency by upregulating target protein expression.